Appln. No. 10/571,291 Amd. dated September 15, 2011 Reply to Office Action of March 15, 2011

Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1(Currently amended). A method for treating diabetes type II, comprising administering to a human or other mammal in need thereof: an effective amount of either 1,3-benzothiazol-2-yl(2-{[4-(morpholin-4-ylmethyl) benzyl]oxy}-pyrimidin-4-yl) acetonitrile or 1,3-benzothiazol-2-yl(2-{[2-(3-pyridinyl)ethyl]amino}-4-pyrimidinyl) acetonitrile—a compound according to formula I

$$R^{1}$$
 S
 $G-L$
 (I)

as well as a tautomer, geometrical isomer, optically active form as enantiomer, diastereomer, racemate, or a pharmaceutically acceptable salt thereof, wherein

G is a pyrimidinyl group;

L is an C_1 - C_6 -alkoxy, an amino group, or a 3-8 membered heterocycloalkyl, containing at least one heteroatom selected from the group consisting of N, O, and S; and

Appln. No. 10/571,291 Amd. dated September 15, 2011 Reply to Office Action of March 15, 2011

 R^{\pm} is selected from the group consisting of hydrogen, sulfonyl, amino, C_{\pm} - C_{6} -alkyl, C_{2} - C_{6} -alkenyl, C_{2} - C_{6} -alkynyl or C_{\pm} - C_{6} -alkoxy, aryl, halogen, cyano and hydroxy.

Claims 2-20 (Cancelled).